<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02013583</url>
  </required_header>
  <id_info>
    <org_study_id>UTSW 062012-080</org_study_id>
    <nct_id>NCT02013583</nct_id>
  </id_info>
  <brief_title>The Glucose Transporter Type I Deficiency (G1D) Registry</brief_title>
  <official_title>The Glucose Transporter Type I Deficiency (G1D) Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this protocol is to create a registry for patients diagnosed with Glucose
      Transporter Type 1 Deficiency (G1D), or patients experiencing symptoms consistent with G1D
      but not yet diagnosed, to enter medical information for physicians and other health
      researchers to analyze to increase the understanding of G1D and any sub-diagnoses.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a registry for patients diagnosed with G1D, or experiencing symptoms G1D but not yet
      diagnosed. The registry will be available online for patients to provide consent, register,
      enter data, and modify data as necessary. The registry will be programmed by programmers at
      UT Southwestern Medical Center. The registry will provide the opportunity for patients to
      enter a comprehensive medical history, from symptoms to lab results to medications and other
      treatment regimens.

      This registry is entirely patient-driven; no medical records will be requested by the
      investigator, nor are visits with the investigator or any other research personnel required.

      The registry database will be periodically &quot;cleaned&quot;; that is, records will be reviewed for
      duplication of entries and consistency of data. Many data validation checks are incorporated
      into the registry. Additional data clarification may be requested from users if users have
      chosen to provide an email address for contact.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Symptom Severity</measure>
    <time_frame>5 years</time_frame>
    <description>It is hypothesized that symptom severity will correspond to the degree of biochemical dysfunction or mutation type (when available). A broad range of symptoms and severity ratings are collected both retrospectively and prospectively.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">750</enrollment>
  <condition>GLUT1 Deficiency Syndrome</condition>
  <condition>Glucose Transporter Type 1 Deficiency Syndrome</condition>
  <condition>Glucose Transporter type1 (GLUT-1) Deficiency</condition>
  <condition>GLUT-1 Deficiency Syndrome</condition>
  <arm_group>
    <arm_group_label>Glucose Transporter Type I Deficiency</arm_group_label>
    <description>No interventions</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>This is an observational registry. No interventions are required or provided.</description>
    <arm_group_label>Glucose Transporter Type I Deficiency</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients will be recruited from the investigator's patients at the Rare Brain Disorders
        Clinic and from the national and international community of patients with Glucose
        Transporter Type I Deficiency
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females

          -  G1D diagnosis

          -  Patients experiencing symptoms of G1D but who have not yet received a diagnosis

        Exclusion Criteria:

          -  Patients who are not experiencing any symptoms of G1D
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan M. Pascual, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Southwestern Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dorothy Kelly, MA</last_name>
    <email>rare.diseases@utsouthwestern.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.g1dregistry.org</url>
    <description>The G1D Registry</description>
  </link>
  <link>
    <url>http://www.utsouthwestern.edu/education/medical-school/departments/neurology/programs/rare-brain-disorders/clinical-trials.html</url>
    <description>The Rare Brain Disorders Program at UT Southwestern: Clinical Research Studies</description>
  </link>
  <reference>
    <citation>Marin-Valencia I, Good LB, Ma Q, Malloy CR, Pascual JM. Heptanoate as a neural fuel: energetic and neurotransmitter precursors in normal and glucose transporter I-deficient (G1D) brain. J Cereb Blood Flow Metab. 2013 Feb;33(2):175-82. doi: 10.1038/jcbfm.2012.151. Epub 2012 Oct 17.</citation>
    <PMID>23072752</PMID>
  </reference>
  <reference>
    <citation>Marin-Valencia I, Good LB, Ma Q, Duarte J, Bottiglieri T, Sinton CM, Heilig CW, Pascual JM. Glut1 deficiency (G1D): epilepsy and metabolic dysfunction in a mouse model of the most common human phenotype. Neurobiol Dis. 2012 Oct;48(1):92-101. doi: 10.1016/j.nbd.2012.04.011. Epub 2012 Apr 23.</citation>
    <PMID>22683290</PMID>
  </reference>
  <reference>
    <citation>Marin-Valencia I, Roe CR, Pascual JM. Pyruvate carboxylase deficiency: mechanisms, mimics and anaplerosis. Mol Genet Metab. 2010 Sep;101(1):9-17. doi: 10.1016/j.ymgme.2010.05.004. Epub 2010 Jun 9. Review.</citation>
    <PMID>20598931</PMID>
  </reference>
  <reference>
    <citation>Wang D, Pascual JM, De Vivo D. Glucose Transporter Type 1 Deficiency Syndrome. 2002 Jul 30 [updated 2018 Mar 1]. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2018. Available from http://www.ncbi.nlm.nih.gov/books/NBK1430/</citation>
    <PMID>20301603</PMID>
  </reference>
  <reference>
    <citation>Pérez-Dueñas B, Prior C, Ma Q, Fernández-Alvarez E, Setoain X, Artuch R, Pascual JM. Childhood chorea with cerebral hypotrophy: a treatable GLUT1 energy failure syndrome. Arch Neurol. 2009 Nov;66(11):1410-4. doi: 10.1001/archneurol.2009.236.</citation>
    <PMID>19901175</PMID>
  </reference>
  <reference>
    <citation>Pascual JM, Campistol J, Gil-Nagel A. Epilepsy in inherited metabolic disorders. Neurologist. 2008 Nov;14(6 Suppl 1):S2-S14. doi: 10.1097/01.nrl.0000340787.30542.41. Review.</citation>
    <PMID>19225367</PMID>
  </reference>
  <reference>
    <citation>Pascual JM, Wang D, Hinton V, Engelstad K, Saxena CM, Van Heertum RL, De Vivo DC. Brain glucose supply and the syndrome of infantile neuroglycopenia. Arch Neurol. 2007 Apr;64(4):507-13. Epub 2007 Feb 12.</citation>
    <PMID>17296829</PMID>
  </reference>
  <reference>
    <citation>Pascual JM, Wang D, Lecumberri B, Yang H, Mao X, Yang R, De Vivo DC. GLUT1 deficiency and other glucose transporter diseases. Eur J Endocrinol. 2004 May;150(5):627-33. Review.</citation>
    <PMID>15132717</PMID>
  </reference>
  <reference>
    <citation>Pascual JM, Wang D, Yang R, Shi L, Yang H, De Vivo DC. Structural signatures and membrane helix 4 in GLUT1: inferences from human blood-brain glucose transport mutants. J Biol Chem. 2008 Jun 13;283(24):16732-42. doi: 10.1074/jbc.M801403200. Epub 2008 Apr 3.</citation>
    <PMID>18387950</PMID>
  </reference>
  <reference>
    <citation>Pascual JM. [Glucose transport hereditary diseases]. Med Clin (Barc). 2006 Nov 11;127(18):709-14. Spanish.</citation>
    <PMID>17169300</PMID>
  </reference>
  <reference>
    <citation>Wang D, Pascual JM, Yang H, Engelstad K, Mao X, Cheng J, Yoo J, Noebels JL, De Vivo DC. A mouse model for Glut-1 haploinsufficiency. Hum Mol Genet. 2006 Apr 1;15(7):1169-79. Epub 2006 Feb 23.</citation>
    <PMID>16497725</PMID>
  </reference>
  <reference>
    <citation>Wang D, Pascual JM, Yang H, Engelstad K, Jhung S, Sun RP, De Vivo DC. Glut-1 deficiency syndrome: clinical, genetic, and therapeutic aspects. Ann Neurol. 2005 Jan;57(1):111-8.</citation>
    <PMID>15622525</PMID>
  </reference>
  <reference>
    <citation>Pascual JM, Lecumberri B, Wang D, Yang R, Engelstad K, De Vivo DC. [Type 1 glucose transporter (Glut1) deficiency: manifestations of a hereditary neurological syndrome]. Rev Neurol. 2004 May 1-15;38(9):860-4. Review. Spanish.</citation>
    <PMID>15152356</PMID>
  </reference>
  <reference>
    <citation>Wang D, Pascual JM, Iserovich P, Yang H, Ma L, Kuang K, Zuniga FA, Sun RP, Swaroop KM, Fischbarg J, De Vivo DC. Functional studies of threonine 310 mutations in Glut1: T310I is pathogenic, causing Glut1 deficiency. J Biol Chem. 2003 Dec 5;278(49):49015-21. Epub 2003 Sep 16.</citation>
    <PMID>13129919</PMID>
  </reference>
  <reference>
    <citation>Pascual JM, Van Heertum RL, Wang D, Engelstad K, De Vivo DC. Imaging the metabolic footprint of Glut1 deficiency on the brain. Ann Neurol. 2002 Oct;52(4):458-64.</citation>
    <PMID>12325075</PMID>
  </reference>
  <reference>
    <citation>Iserovich P, Wang D, Ma L, Yang H, Zuniga FA, Pascual JM, Kuang K, De Vivo DC, Fischbarg J. Changes in glucose transport and water permeability resulting from the T310I pathogenic mutation in Glut1 are consistent with two transport channels per monomer. J Biol Chem. 2002 Aug 23;277(34):30991-7. Epub 2002 May 24.</citation>
    <PMID>12032147</PMID>
  </reference>
  <reference>
    <citation>De Vivo DC, Wang D, Pascual JM, Ho YY. Glucose transporter protein syndromes. Int Rev Neurobiol. 2002;51:259-88. Review.</citation>
    <PMID>12420362</PMID>
  </reference>
  <reference>
    <citation>Brockmann K, Wang D, Korenke CG, von Moers A, Ho YY, Pascual JM, Kuang K, Yang H, Ma L, Kranz-Eble P, Fischbarg J, Hanefeld F, De Vivo DC. Autosomal dominant glut-1 deficiency syndrome and familial epilepsy. Ann Neurol. 2001 Oct;50(4):476-85.</citation>
    <PMID>11603379</PMID>
  </reference>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2013</study_first_submitted>
  <study_first_submitted_qc>December 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2013</study_first_posted>
  <last_update_submitted>December 26, 2013</last_update_submitted>
  <last_update_submitted_qc>December 26, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Juan Pascual</investigator_full_name>
    <investigator_title>Associate Professor, Director of the Rare Brain Disorders Program</investigator_title>
  </responsible_party>
  <keyword>Glucose Transporter Type I Deficiency</keyword>
  <keyword>Glucose Transporter Type 1 Deficiency</keyword>
  <keyword>G1D</keyword>
  <keyword>Glut1 Deficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Carbohydrate Metabolism, Inborn Errors</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

